Verona Pharma plc Verona Pharma's Shelf Registration Statement Declared Effective By Sec

 
TIDMVRP 
 
 
   LONDON, June 4, 2018 (GLOBE NEWSWIRE) - Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage 
biopharmaceutical company focused on developing and commercializing 
innovative therapies for the treatment of respiratory diseases, is 
pleased to announce that its shelf registration statement on Form F-3 
(the "Shelf Registration Statement") filed with the Securities and 
Exchange Commission (the "SEC") on May 23, 2018 was declared effective 
by the SEC on June 1, 2018. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
clinical trials, treatment with RPL554 has been observed to result in 
statistically significant improvements in lung function and clinical 
symptoms as compared to placebo, and has shown clinically meaningful and 
statistically significant improvements in lung function when 
administered in addition to frequently used short- and long-acting 
bronchodilators as compared to such bronchodilators administered as a 
single agent. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and 
potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser   Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

June 04, 2018 02:00 ET (06:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.